Literature DB >> 30917955

Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.

Inhye E Ahn1, Neil Basumallik1,2, Xin Tian3, Susan Soto1, Adrian Wiestner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30917955      PMCID： PMC6543520          DOI： 10.1182/blood.2019896688

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  18 in total

1.  Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Carol Moreno; Richard Greil; Fatih Demirkan; Alessandra Tedeschi; Bertrand Anz; Loree Larratt; Martin Simkovic; Olga Samoilova; Jan Novak; Dina Ben-Yehuda; Vladimir Strugov; Devinder Gill; John G Gribben; Emily Hsu; Chih-Jian Lih; Cathy Zhou; Fong Clow; Danelle F James; Lori Styles; Ian W Flinn
Journal:  Lancet Oncol       Date:  2018-12-03       Impact factor: 41.316

2.  Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.

Authors:  Anthony R Mato; Colleen Timlin; Chaitra Ujjani; Alan Skarbnik; Christina Howlett; Rahul Banerjee; Chadi Nabhan; Stephen J Schuster
Journal:  Br J Haematol       Date:  2017-02-21       Impact factor: 6.998

3.  Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.

Authors:  Philip A Thompson; Susan M O'Brien; William G Wierda; Alessandra Ferrajoli; Francesco Stingo; Susan C Smith; Jan A Burger; Zeev Estrov; Nitin Jain; Hagop M Kantarjian; Michael J Keating
Journal:  Cancer       Date:  2015-07-20       Impact factor: 6.860

4.  Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.

Authors: 
Journal:  Haematologica       Date:  2016-10-18       Impact factor: 9.941

5.  Analysis of survival by tumor response.

Authors:  J R Anderson; K C Cain; R D Gelber
Journal:  J Clin Oncol       Date:  1983-11       Impact factor: 44.544

6.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Authors:  Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

7.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

8.  BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Authors:  Jennifer A Woyach; Amy S Ruppert; Daphne Guinn; Amy Lehman; James S Blachly; Arletta Lozanski; Nyla A Heerema; Weiqiang Zhao; Joshua Coleman; Daniel Jones; Lynne Abruzzo; Amber Gordon; Rose Mantel; Lisa L Smith; Samantha McWhorter; Melanie Davis; Tzyy-Jye Doong; Fan Ny; Margaret Lucas; Weihong Chase; Jeffrey A Jones; Joseph M Flynn; Kami Maddocks; Kerry Rogers; Samantha Jaglowski; Leslie A Andritsos; Farrukh T Awan; Kristie A Blum; Michael R Grever; Gerard Lozanski; Amy J Johnson; John C Byrd
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 50.717

9.  Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Authors:  Erika Tissino; Dania Benedetti; Sarah E M Herman; Elisa Ten Hacken; Inhye E Ahn; Kari G Chaffee; Francesca Maria Rossi; Michele Dal Bo; Pietro Bulian; Riccardo Bomben; Elisabeth Bayer; Andrea Härzschel; Julia Christine Gutjahr; Massimiliano Postorino; Enrico Santinelli; Ayed Ayed; Francesco Zaja; Annalisa Chiarenza; Gabriele Pozzato; Alexandre Chigaev; Larry A Sklar; Jan A Burger; Alessandra Ferrajoli; Tait D Shanafelt; Adrian Wiestner; Giovanni Del Poeta; Tanja Nicole Hartmann; Valter Gattei; Antonella Zucchetto
Journal:  J Exp Med       Date:  2018-01-04       Impact factor: 14.307

10.  Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.

Authors:  Inhye E Ahn; Mohammed Z H Farooqui; Xin Tian; Janet Valdez; Clare Sun; Susan Soto; Jennifer Lotter; Stephanie Housel; Maryalice Stetler-Stevenson; Constance M Yuan; Irina Maric; Katherine R Calvo; Pia Nierman; Thomas E Hughes; Nakhle S Saba; Gerald E Marti; Stefania Pittaluga; Sarah E M Herman; Carsten U Niemann; Lone B Pedersen; Christian H Geisler; Richard Childs; Georg Aue; Adrian Wiestner
Journal:  Blood       Date:  2018-02-26       Impact factor: 22.113
View more
  9 in total

1.  Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.

Authors:  Sigrid S Skånland; Anthony R Mato
Journal:  Blood Adv       Date:  2021-01-12

2.  Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.

Authors:  Paul J Hampel; Hua-Jay J Cherng; Timothy G Call; Wei Ding; Mahsa Khanlari; Ellen D McPhail; Roberto N Miranda; Pei Lin; Hussein A Tawbi; Alessandra Ferrajoli; William G Wierda; Nitin Jain; Sameer A Parikh
Journal:  Blood Adv       Date:  2020-09-22

3.  Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.

Authors:  Paul J Hampel; Timothy G Call; Kari G Rabe; Wei Ding; Eli Muchtar; Saad S Kenderian; Yucai Wang; Jose F Leis; Thomas E Witzig; Amber B Koehler; Amie L Fonder; Susan M Schwager; Daniel L Van Dyke; Esteban Braggio; Susan L Slager; Neil E Kay; Sameer A Parikh
Journal:  Oncologist       Date:  2020-09-20

Review 4.  Managing toxicities of Bruton tyrosine kinase inhibitors.

Authors:  Andrew Lipsky; Nicole Lamanna
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

5.  Efficacy, safety, and quality of life of generic and innovator ibrutinib in Indian CLL patients.

Authors:  Charanpreet Singh; Nishant Jindal; Padma Youron; Pankaj Malhotra; Gaurav Prakash; Alka Khadwal; Arihant Jain; Sreejesh Sreedharanunni; Man Updesh Singh Sachdeva; Shano Naseem; Neelam Varma; Subhash Varma; Deepesh P Lad
Journal:  Indian J Hematol Blood Transfus       Date:  2020-11-13       Impact factor: 0.900

Review 6.  Determining drug dose in the era of targeted therapies: playing it (un)safe?

Authors:  Sigrid S Skånland; Geir E Tjønnfjord
Journal:  Blood Cancer J       Date:  2022-08-23       Impact factor: 9.812

7.  An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following Ibrutinib Discontinuation.

Authors:  Stefano Pozzi; Leonardo Potenza; Davide Giusti; Elisabetta Colaci; Valeria Pioli; Giovanna Leonardi; Monica Maccaferri; Mario Luppi; Roberto Marasca
Journal:  Am J Case Rep       Date:  2022-08-26

8.  Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study.

Authors:  Jeremie Zerbit; Sylvie Chevret; Sophie Bernard; Marie Kroemer; Charlotte Ablard; Stephanie Harel; Pauline Brice; Isabelle Madelaine; Catherine Thieblemont
Journal:  Ann Hematol       Date:  2020-06-01       Impact factor: 3.673

9.  The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study.

Authors:  Anthony R Mato; Jeff P Sharman; Juliana M L Biondo; Mei Wu; Yong Mun; Su Y Kim; Kathryn Humphrey; Michelle Boyer; Qian Zhu; John F Seymour
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.